

INOVIO PHARMACEUTICALS, INC.

Form 8-K

August 03, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report**

**(Date of earliest event reported)**

**July 28, 2016**

**INOVIO PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction)**

**001-14888**  
**(Commission)**

**33-0969592**  
**(I.R.S. Employer)**

**of incorporation)**

**File Number)**

**Identification No.)**

**660 W. Germantown Pike, Suite 110**

**Plymouth Meeting, Pennsylvania**  
**(Address of principal executive offices)**

**19462**  
**(Zip Code)**

**Registrant's telephone number, including area code: (267) 440-4200**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement.

On July 28, 2016, we received a notice of termination of the Collaboration, Option and License Agreement by and between F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. and Inovio Pharmaceuticals, Inc., dated September 9, 2013. The termination will be effective 90 days after the notice date.

On August 3, 2016, we issued a press release, which we file as Exhibit 99.1 to, and incorporate by reference in, this Form 8-K current report as though fully set forth herein, announcing our plans to continue to develop our hepatitis B DNA vaccine (INO-1800) and independently advance our phase I study of INO-1800.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Exhibit Description
99.1	Press Release dated August 3, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.

By: /s/ Peter Kies  
Peter Kies,  
Chief Financial Officer

Date: August 3, 2016